- Home
- SPFI vs RXST Comparison
SPFI vs RXST Comparison
Compare SPFI & RXST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPFI | RXST |
|---|---|---|
| Founded | 1941 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.0M | 524.6M |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SPFI | RXST |
|---|---|---|
| Price | $39.56 | $11.46 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 11 |
| Target Price | ★ $41.75 | $11.30 |
| AVG Volume (30 Days) | 56.5K | ★ 824.6K |
| Earning Date | 01-23-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.61% | N/A |
| EPS Growth | ★ 36.91 | N/A |
| EPS | ★ 3.51 | N/A |
| Revenue | ★ $205,251,000.00 | $142,085,000.00 |
| Revenue This Year | $13.52 | N/A |
| Revenue Next Year | $6.28 | $4.26 |
| P/E Ratio | $11.30 | ★ N/A |
| Revenue Growth | ★ 11.60 | 10.75 |
| 52 Week Low | $30.01 | $6.32 |
| 52 Week High | $42.38 | $37.13 |
Technical Indicators
Market Signals| Indicator | SPFI | RXST |
|---|---|---|
| Relative Strength Index (RSI) | 53.06 | 49.18 |
| Support Level | $40.60 | $10.46 |
| Resistance Level | $41.50 | $13.14 |
| Average True Range (ATR) | 0.92 | 0.67 |
| MACD | -0.10 | -0.25 |
| Stochastic Oscillator | 33.12 | 36.23 |
Price Performance
Historical ComparisonAbout SPFI South Plains Financial Inc.
South Plains Financial Inc operates as a bank holding company. The company provides a wide range of commercial and consumer financial services to small and medium-sized businesses and individuals. The principal business activities include commercial and retail banking, along with insurance, investment, trust, and mortgage services. The company has one reportable segment: banking.
About RXST RxSight Inc.
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.